JERUSALEM–(BUSINESS WIRE)–May 23, 2018– Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for…Original Article
Teva Confirms September PDUFA Date for Fremanezumab
